Table 7.
Results of the omega-3 index and availability of DHA and EPA in the study groups.
| Variable | Baseline | Final (8 Weeks) |
Within-Group p Value |
Between-Group p Value |
|---|---|---|---|---|
| Omega-3 index | ||||
| Placebo | 5.64 ± 0.88 | 5.45 ± 0.70 | 0.251 | 0.001 |
| Boswellia | 5.88 ± 1.01 | 5.50 ± 0.87 | 0.024 | |
| AvailOm® | 5.58 ± 1.11 | 6.10 ± 1.00 | 0.002 | |
| Boswellia + AvailOm® | 5.35 ± 0.98 | 6.02 ± 1.42 | 0.001 | |
| DHA, % | ||||
| Placebo | 3.29 ± 0.60 | 3.12 ± 0.49 | 0.098 | 0.022 |
| Boswellia | 3.38 ± 0.60 | 3.17 ± 0.55 | 0.038 | |
| AvailOm® | 3.16 ± 0.70 | 3.22 ± 0.60 | 0.507 | |
| Boswellia + AvailOm® | 3.02 ± 0.64 | 3.19 ± 0.83 | 0.050 | |
| EPA, % | ||||
| Placebo | 0.50 ± 0.23 | 0.51 ± 0.19 | 0.970 | 0.001 |
| Boswellia | 0.63 ± 0.35 | 0.50 ± 0.28 | 0.058 | |
| AvailOm® | 0.59 ± 0.37 | 0.97 ± 0.39 | 0.001 | |
| Boswellia + AvailOm® | 0.52 ± 0.27 | 0.94 ± 0.48 | 0.001 |
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid.